Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $31.86.

A number of research firms recently commented on BCAX. Wall Street Zen downgraded Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. HC Wainwright cut their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a report on Friday, May 16th. Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price for the company in a report on Friday. Finally, Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Friday.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds have recently modified their holdings of the company. California State Teachers Retirement System purchased a new stake in Bicara Therapeutics in the fourth quarter valued at $25,000. CWM LLC purchased a new position in shares of Bicara Therapeutics in the first quarter valued at approximately $29,000. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics in the fourth quarter worth $31,000. BNP Paribas Financial Markets acquired a new position in Bicara Therapeutics during the 4th quarter worth $32,000. Finally, Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $33,000.

Bicara Therapeutics Trading Up 7.7%

NASDAQ BCAX traded up $0.71 during trading on Friday, reaching $9.98. 2,037,384 shares of the company's stock traded hands, compared to its average volume of 541,123. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $28.09. The company's 50 day simple moving average is $12.84 and its two-hundred day simple moving average is $14.73.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). Equities analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.